252 related articles for article (PubMed ID: 21288628)
21. Use of drospirenone/ethinyl estradiol (DRSP/EE) among women with acne reduces acne treatment-related resources.
Joish VN; Boklage S; Lynen R; Schmidt A; Lin J
J Med Econ; 2011; 14(6):681-9. PubMed ID: 21892859
[TBL] [Abstract][Full Text] [Related]
22. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
23. Advances in the treatment of acne.
Kimball AB
J Reprod Med; 2008 Sep; 53(9 Suppl):742-52. PubMed ID: 18980046
[TBL] [Abstract][Full Text] [Related]
24. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris.
Olson WH; Lippman JS; Robisch DM
Int J Fertil Womens Med; 1998; 43(6):286-90. PubMed ID: 9920537
[TBL] [Abstract][Full Text] [Related]
25. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens.
Kelekci KH; Kelekci S; Yengel I; Gul S; Yilmaz B
J Dermatolog Treat; 2012 Jun; 23(3):177-83. PubMed ID: 21254871
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.
Palombo-Kinne E; Schellschmidt I; Schumacher U; Gräser T
Contraception; 2009 Apr; 79(4):282-9. PubMed ID: 19272497
[TBL] [Abstract][Full Text] [Related]
27. Estradiol + nomegestrol. Oral contraceptive claimed to be more natural, but presenting no obvious advantages.
Prescrire Int; 2012 Dec; 21(133):292. PubMed ID: 23373095
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
Batukan C; Muderris II
Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen.
Hernádi L; Marr J; Trummer D; De Leo V; Petraglia F
Contraception; 2009 Jul; 80(1):18-24. PubMed ID: 19501211
[TBL] [Abstract][Full Text] [Related]
30. Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone.
Dickerson V
J Reprod Med; 2002 Nov; 47(11 Suppl):985-93. PubMed ID: 12497673
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
[TBL] [Abstract][Full Text] [Related]
32. Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma.
Taniguchi F; Enatsu A; Ota I; Toda T; Arata K; Harada T
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():116-20. PubMed ID: 26115056
[TBL] [Abstract][Full Text] [Related]
33. Hormonal contraceptives for acne management.
Rich P
Cutis; 2008 Jan; 81(1 Suppl):13-8. PubMed ID: 18338653
[TBL] [Abstract][Full Text] [Related]
34. A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism.
Oner G; Muderris II
Contraception; 2011 Nov; 84(5):508-11. PubMed ID: 22018126
[TBL] [Abstract][Full Text] [Related]
35. Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis.
Anttila L; Neunteufel W; Petraglia F; Marr J; Kunz M
Clin Drug Investig; 2011; 31(8):519-525. PubMed ID: 21721590
[TBL] [Abstract][Full Text] [Related]
36. [Short-term effect of an estroprogestin containing ethinylestradiol 20 mcg + drospirenone 3 mg in 24+4 regimen at hormonal and cutaneous level in ovarian hyperandrogenism].
Lello S; Pacifico V; Primavera G; Guardianelli F; Sorge R; Paoletti AM; Melis GB; Raskovic D; Colonna L
Minerva Ginecol; 2010 Dec; 62(6):509-13. PubMed ID: 21079572
[TBL] [Abstract][Full Text] [Related]
37. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
[TBL] [Abstract][Full Text] [Related]
38. Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial.
Machado RB; Pompei LM; Badalotti M; Ferriani R; Cruz AM; Nahas E; Maia H
Eur J Contracept Reprod Health Care; 2017 Feb; 22(1):11-16. PubMed ID: 27684740
[TBL] [Abstract][Full Text] [Related]
39. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Niknian M; Shulman LP; Lynen R
Contraception; 2011 Jul; 84(1):81-6. PubMed ID: 21664515
[TBL] [Abstract][Full Text] [Related]
40. Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study.
Klipping C; Duijkers I; Fortier MP; Marr J; Trummer D; Elliesen J
J Fam Plann Reprod Health Care; 2012 Apr; 38(2):73-83. PubMed ID: 22454003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
